Developing novel strategies to overcome the immunosuppressive tumor microenvironment is a critically important area of cancer therapy research. Here, the authors assess the therapeutic potential of CD244 (2B4/signaling lymphocyte activation molecule family 4), an immunoregulatory receptor found...
Presentation slides and video from the 2020 Advances in Cancer Immunotherapy TM - Charleston, SC, held on February 1, 2020 are available here. Program Organizers David M. Neskey, MD – MUSC Hollings Cancer Center Chrystal M. Paulos, PhD – Medical University of South Carolina ...
19 attachments
Presentation slides and video from the 2020 Advances in Cancer Immunotherapy TM – Charlotte, NC, held on January 23, 2020 are available here. Program Organizers Asim Amin, MD, PhD – Levine Cancer Institute Nilanjan Ghosh, MD, PhD – Levine Cancer Institute, Atrium Health Marina...
20 attachments
Learning you have head and neck cancer can fell overwhelming. Give yourself time to digest the news, and then focus on learning as much as you can about your exact diagnosis. Knowing ket information will better prepare you to make well-informed decisions with your doctor. This guide, published...
2019 Immunotherapy H&N.pdf
Immunotherapy, especially immune checkpoint inhibition, has provided powerful tools against cancer. The authors aimed to detect the expression of common immune checkpoints and evaluate their prognostic values in nasopharyngeal carcinoma (NPC). They concluded that the expression status of nine...
Thymic epithelial tumors are PD-L1–expressing tumors of thymic epithelial origin characterized by varying degrees of lymphocytic infiltration and a predisposition towards development of paraneoplastic autoimmunity. PD-1–targeting antibodies have been evaluated, largely in patients with thymic...
Standard treatment of oropharyngeal squamous cell carcinoma (OPSCC) is associated with high morbidity, whereas immunotherapeutic approaches using PD-1:PD-L1 checkpoint blockade only show moderate response rates in OPSCC patients. Therefore, a better stratification of patients and the development...
The US is experiencing an epidemic of HPV + oropharyngeal cancers (OPC), the rates and burden of which now exceed that for cervical cancer. Immunotherapy targeting programmed death 1 (PD-1) on tumor-infiltrating lymphocytes and/or its ligand PD-L1 on tumor cells, which was effective in...
Presentation slides and video from the 2019 Advances in Cancer Immunotherapy TM - San Diego, CA, held on December 12, 2019 are available here. Program Organizers Christopher Coyne, MD, MPH – University of California San Diego Sandip P. Patel, MD – University of California San...
From the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) post-program webinar recording for the Dallas event is provided here. The purpose of...
Advances in Cancer Immunotherapy™ Post-Program Webinar 1 (Dallas).mp4
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us